View Shannon Grande Contrastano presentation from AGSCT23.
2023 ASGCT – Kelonia Presentation
Presentation: Potent in vivo transduction by iGPS particles generates CAR T cells with durable anti-tumor activity
Recent News
Recent Press Release
Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma
KLN-1010 is the first anti-BCMA in vivo CAR-T program studied in a multi-center clinical trial KLN-1010 is administered directly to patients without apheresis, ex vivo manufacturing or lymphodepletion BOSTON--Kelonia Therapeutics, Inc., a biotech company...
Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
BOSTON, Mass., May 9, 2025 - Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the...
Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
BOSTON, Mass., May 2, 2024 - Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming...